12 results about "Cytolysis" patented technology

The application belongs to the technical field of microbial fermentation, and particularly relates to a kind of cytolysis product of mixed bacteria fermentation and a preparation method. The cytolysis product is prepared by mixed bacteria fermentation of two kinds of aerobic probiotics, i.e. Lactobacillus plantarum and Aspergillus oryzae are used as fermentation strains to carry out mixed bacteria fermentation treatment on rice milk, and membrane filtration and column chromatography system are used for filtration and enrichment, so as to obtain a cytolysis fermentation product filtrate rich in kojic acid, the content of kojic acid is greater than 200 g / L, which is significantly improved compared with conventional process. The obtained cytolysis product has no bad smell and clear color, so that the beneficial function of kojic acid can be played only with a low addition amount in cosmetics, and the addition of odor masking and color correcting auxiliaries is reduced, and the cytolysis product can be used for preparing cosmetics with skin repair, whitening and other functions.

Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells predicts poor outcome of patients treated with anti-PD1 (e.g. pembrolizumab). Finally, the combination of anti-NRP1 and anti-PD1 antibodies is synergistic in human, specifically in CD8+ T-cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PD1 antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed.

To provide anti- CD3 antibodies that more closely mimic TCR / MHC interactions and are desirable for minimizing the release of toxic cytokines while maintaining effective tumor cytolysis.SOLUTION: Novel human CD3 antigen binding polypeptides and their preparation and their use in the treatment and / or diagnosis of various diseases, as well as bispecific antibody molecules capable of activating immune effector cells and their use in the diagnosis and / or treatment of various diseases. In some embodiments, the anti-CD3 antibody is characterized or selected to have a reduced tendency to induce cytokine release upon binding to a competent T cell, e.g., due to the release of IL-2 and IFN γ.SELECTED DRAWING: Figure 1

A combination therapeutic strategy employs multiple oncolytic viruses (OVs), grouped and administered based on their virological properties, tumor selectivity, and distinct antigen profiles, to treat malignant tumors. Representative groupings may include members of flaviviruses, each contributing distinct immune modulation and the same modes of tumor cell killing. A predefined treatment schedule involves sequential or concurrent administration of antigenically diverse OVs in multiple cycles, reducing cross-neutralization and sustaining cytolytic pressure on tumors. A pre-characterized OV panel, comprising members from a virus family, RNA and DNA viruses, both wild-type and genetically engineered, serves as a flexible resource for customizing treatment regimens by tumor type, immune landscape, and therapeutic goals. This platform establishes a rational framework for combination OV therapy with improved durability, safety, and clinical effectiveness.

Evaluating immune and cancer cells is provided for by assessing cytolysis of cancer cells by effector cells, which includes: providing a cell-substrate impedance monitoring device operably connected to an impedance analyzer, wherein the device comprises a well for receiving cells and an electrode array at a base of the well, the device further operably connected to an imaging unit; b) adding target cells characterized as cancer cells to the well; c) disposing a layer comprising an extracellular matrix (ECM) over the target cells; d) adding effector cells over the ECM layer; and e) imaging the well and monitoring cell-substrate impedance of the well to determine invasion of the effector cells through the ECM layer and effectiveness of effector cell killing of the target cells either directly or via migration and invasion through extracellular matrix.

The present invention relates to a modified immune cell for use in the treatment of a solid tumor in a subject wherein the modified immune cell comprises one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancer cell of said solid tumor, in said immune cell, nuclear receptor subfamily group 2 F member 6 (NR2F6) activity is suppressed (as compared to a control immune cell), and binding of the immune cell to an antigen is associated with death of the cancer cell expressing the antigen, and inducing a secondary immune response against a cancer cell of a solid tumor in a subject, the secondary immune response is non-specific (epitope diffusion) for the antigen targeted to the transgenic construct. The present invention also relates to a modified immune cell comprising one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancer cell of a solid tumor in which NR2F6 activity and Casite B line lymphoma oncogene-b (CBLB) activity are inhibited (as compared to a control immune cell). The invention also relates to pharmaceutical compositions comprising a modified immune cell suitable for the treatment of solid tumors, additionally comprising a pharmaceutically acceptable carrier, and to in vitro methods for enhancing the cytolytic activity of the modified immune cell.

Disclosed is a method and device / apparatus for determination of the contribution from lysed cells to measurement values of an analyte present in the extracellular compartment. The method employs multiple tandem measurements of analyte and an intracellular marker from samples where different numbers of cells are lysed so as to establish the relationship between the measured value of the intracellular marker and the analyte.

This application relates to therapeutic combinations of BTN3A-activating antibodies with immune checkpoint inhibitors selected from LAG-3 inhibitors (anti-LAG-3 antibodies and LAG-3 fusion proteins), anti-TIGIT antibodies, or anti-TIM-3 antibodies, which are particularly useful for treating cancer. More specifically, this disclosure relates to the combination of BTN3A-activating antibodies that specifically bind to BTN3A and activate the cytolytic function of Vy9V52 T cells with LAG-3 inhibitors that can directly bind to LAG-3 molecules or their ligands and block the interaction of LAG-3 with these ligands to promote a cooperative anti-tumor effect.

Provided is a method with which it is possible to easily measure lysosomal activity of cells in a sample. A method for measuring the activity of lysosome in a cell in vitro, said method comprising the following steps (1)-(4): (1) a step for culturing a cell by adding a fluorescent substance-binding protein to a cell-containing medium; (2) a step for collecting the cultured cells after step (1); (3) a step for adding a composition for cell lysis to the cultured cells collected in step (2) to obtain a cell lysate component; and (4) a step for measuring the fluorescence intensity of the fluorescent substance-bound protein in the cell lysate component obtained in step (3).

The disclosure provides, in various embodiments, polynucleotides and vectors comprising sequences encoding a mono-specific or a bi-specific CAR that is capable of binding to a first TAA, or a T-cell engager that is capable of binding to CD3 and a second TAA, or a combination thereof. The disclosure also provides, in various embodiments, T lymphocytes comprising one or more of the polynucleotides or vectors; compositions (e.g., pharmaceutical compositions) and kits comprising one or more of the T lymphocytes; methods of treating a cancer in mammalian subject (e.g., a human), and methods of inducing T cell-mediated cytolysis of cancer cells (e.g., solid tumor cells).

The disclosure is generally related to nanoparticles have an oxidized tumor cell lysate encapsulated therein and oligonucleotides on the surface thereof. Methods of making and using the nanoparticles are also provided herein.

Providing a human 4-1BB agonist antibody and a method for using it. [Solution] Isolated monoclonal antibodies or recombinant monoclonal antibodies that bind to 4-1BB are provided. In some cases, the antibodies of the embodiments can be used for the detection, diagnosis and / or therapeutic treatment of human diseases such as cancer. Increasing evidence has shown that anti-4-1BB monoclonal antibodies have strong antitumor properties, which in itself is due to their potent CD8 + This results in T cell activation, IFN-γ production, and induction of cytolytic markers. However, the need for improved human 4-1BB antibodies remains unmet. This disclosure provides a means to address this problem.